Shattuck Labs(NASDAQ) STTK

Shattuck Labs, Inc. creates medicines for patients with inflammatory diseases. These drugs help the body control its immune response. The company focuses on treating conditions like Crohn's disease.

What Shattuck Is Building

• SL-325: Monoclonal antibody designed to block Death Receptor 3, which is a protein that triggers inflammation; targets Crohn's disease.
• SL-846: Bispecific antibody engineered to block both Death Receptor 3 and Interleukin-23 receptors simultaneously to treat immune disorders.
• Subcutaneous Autoinjector: High-concentration drug formulation designed for use in self-administered injector pens for patient convenience.

The Roadmap for New Drugs

• Completed Phase 1 trials for lead candidate SL-325 in healthy volunteers during June 2026.
• Initiated a toxicology study in primates for the bispecific candidate SL-846 to prepare for human trials.
• Raised $86.2 million through a public stock offering in June 2026 to fund clinical development.
• Discontinued the development of the oncology compound SL-172154 during the 2026 fiscal year.

A Different Way to Block Inflammation

Shattuck blocks the Death Receptor 3 directly to ensure more complete suppression of inflammation compared to competitors targeting the ligand protein. The company aims to provide quarterly dosing options to improve treatment convenience for patients with chronic conditions.

Key Financial Figures

• Net loss was $29.9 million for the six months ended June 30, 2026, up 14.4% year over year.
• Research and development expenses rose 21.8% to $22.6 million for the six-month period ended June 30, 2026.
• Cash and short-term investments totaled $208.3 million as of June 30, 2026.
• Common stock warrants exercised during the first half of 2026 generated $52.8 million in gross proceeds.
• Management expects existing capital will support operations into 2029.

Bottom Line

Shattuck has evolved from oncology research to focus on inflammatory disease treatments. Its sustainability depends on successfully advancing its drug candidates through clinical trials without current product revenue.